Overview
IONS market data
Price History
IONS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IONS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89Benzinga · Jul 21, 2026, 1:46 PM
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For ThursdayBenzinga · Jul 16, 2026, 11:15 AM
Wolfe Research Downgrades Ionis Pharmaceuticals to Peer PerformBenzinga · Jul 16, 2026, 10:40 AM
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines ExpandGlobenewswire Inc · Jul 15, 2026, 11:15 AM
Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of BoxesBenzinga · Jul 14, 2026, 1:17 PM
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $85Benzinga · Jul 13, 2026, 2:11 PM
Ionis Pharmaceuticals Doses First Participant In Phase 1-2 ASCEND Study Of Ion337 For Dravet Syndrome, A Neurological DisorderBenzinga · Jul 13, 2026, 11:03 AM
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to GainBenzinga · Jul 10, 2026, 3:35 PM
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $125Benzinga · Jul 10, 2026, 2:20 PM
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $110Benzinga · Jul 10, 2026, 1:55 PM